Descriptive analysis of MRI functional changes occurring during reduced dose radiotherapy for myxoid liposarcomas.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Oct 2021
Historique:
entrez: 21 9 2021
pubmed: 22 9 2021
medline: 28 9 2021
Statut: ppublish

Résumé

Myxoid liposarcomas (MLS) show enhanced response to radiotherapy due to their distinctive vascular pattern and therefore could be effectively treated with lower radiation doses. This is a descriptive study to explore the use of functional MRI to identify response in a uniform cohort of MLS patients treated with reduced dose radiotherapy. 10 patients with MLS were imaged pre-, during, and post-radiotherapy receiving reduced dose radiotherapy and the response to treatment was histopathologically assessed post-radiotherapy. Apparent diffusion coefficient (ADC), T2* relaxation time, volume transfer constant (Ktrans), initial area under the gadolinium curve over 60 s (IAUGC60) and (Gd) were estimated for a central tumour volume. All parameters showed large inter- and intrasubject variabilities. Pre-treatment (Gd), IAUGC60 and Ktrans were significantly different between responders and non-responders. Post-radiotherapy reductions from baseline were demonstrated for T2*, (Gd), IAUGC60 and Ktrans for responders. No statistically significant ADC differences were demonstrated between the two response groups. Significantly greater early tumour volume reductions were observed for responders. MLS are heterogenous lesions, characterised by a slow gradual contrast-agent uptake. Pre-treatment vascular parameters, early changes to tumour volume, vascular parameters and T2* have potential in identifying response to treatment. The delayed (Gd) is a suitable descriptive parameter, relying simply on T1 measurements. Volume changes precede changes in MLS functionality and could be used to identify early response. MLS are are characterised by slow gradual contrast-agent uptake. Measurement of the delayed contrast-agent uptake (Gd) is simple to implement and able to discriminate response.

Identifiants

pubmed: 34545764
doi: 10.1259/bjr.20210310
pmc: PMC9328045
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20210310

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Radiology. 2012 Nov;265(2):426-36
pubmed: 22891356
Int J Radiat Biol. 2009 Sep;85(9):805-13
pubmed: 19728195
Front Cardiovasc Med. 2017 Oct 26;4:66
pubmed: 29124057
Eur Radiol. 2012 Jul;22(7):1451-64
pubmed: 22562143
Clin Orthop Relat Res. 2002 Apr;(397):212-27
pubmed: 11953613
JAMA Oncol. 2021 Jan 01;7(1):e205865
pubmed: 33180100
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):760-5
pubmed: 17892916
Magn Reson Med. 2013 Oct;70(4):954-61
pubmed: 23943610
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):522-6
pubmed: 15380587
Phys Med Biol. 2006 Jul 21;51(14):3593-602
pubmed: 16825751
J Magn Reson Imaging. 2008 May;27(5):1109-13
pubmed: 18425832
Acta radiol. 1960 Sep;54:225-39
pubmed: 13702022
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1480-7
pubmed: 18448271
Orthop Traumatol Surg Res. 2013 Feb;99(1 Suppl):S115-23
pubmed: 23380432
Spine J. 2016 Mar;16(3):291-8
pubmed: 26325017
Front Oncol. 2019 Apr 25;9:280
pubmed: 31106141
Ann Surg Oncol. 2010 Oct;17(10):2578-84
pubmed: 20556523
Acta Radiol. 2014 Oct;55(8):952-60
pubmed: 24123962
Magn Reson Imaging. 2018 Jul;50:1-9
pubmed: 29476781
Blood. 2006 Apr 1;107(7):2912-9
pubmed: 16339404
Eur Radiol. 2016 Jul;26(7):1991-8
pubmed: 26385804
Magn Reson Med. 2006 Mar;55(3):566-74
pubmed: 16450365
Tomography. 2016 Dec;2(4):308-316
pubmed: 28066805
Magn Reson Med. 2009 Aug;62(2):357-64
pubmed: 19526495
Cancer. 2009 Jul 15;115(14):3254-61
pubmed: 19472403
Eur J Surg Oncol. 2014 Apr;40(4):394-401
pubmed: 24534361
Eur Radiol. 2004 Jun;14(6):959-63
pubmed: 14767604
J Magn Reson Imaging. 2007 Jun;25(6):1199-204
pubmed: 17520732
Neoplasia. 2009 Mar;11(3):247-59, 2p following 259
pubmed: 19242606
Oncologist. 2009 Oct;14(10):1021-38
pubmed: 19789392
Radiology. 1998 Jan;206(1):227-35
pubmed: 9423677
Radiology. 2016 Mar;278(3):831-40
pubmed: 26390048
Phys Med. 2019 Apr;60:76-82
pubmed: 31000090
Magn Reson Med. 2002 Dec;48(6):980-6
pubmed: 12465107
Magn Reson Imaging. 2018 Oct;52:53-61
pubmed: 29859948
Magn Reson Med. 1987 Nov;5(5):399-416
pubmed: 3431401
J Magn Reson Imaging. 2016 Jul;44(1):72-80
pubmed: 26800280
J Magn Reson Imaging. 2015 Jan;41(1):132-41
pubmed: 24753433
Radiother Oncol. 2010 Dec;97(3):404-7
pubmed: 21040989
Contrast Media Mol Imaging. 2013 Jul-Aug;8(4):340-9
pubmed: 23613437
Radiographics. 2000 Jul-Aug;20(4):1007-19
pubmed: 10903690
JACC Basic Transl Sci. 2018 Aug 28;3(4):563-572
pubmed: 30175280
Radiol Case Rep. 2017 Aug 12;12(4):811-814
pubmed: 29484077
Magn Reson Med. 2006 Nov;56(5):993-1000
pubmed: 17036301
Radiology. 2010 Aug;256(2):348-64
pubmed: 20656830
Radiology. 2010 Dec;257(3):643-52
pubmed: 20858850
AJR Am J Roentgenol. 1996 Apr;166(4):829-33
pubmed: 8610559
MAGMA. 2004 Dec;17(3-6):296-302
pubmed: 15480945
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
Phys Med Biol. 2008 Mar 7;53(5):1225-39
pubmed: 18296759

Auteurs

Evanthia Kousi (E)

MRI unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.

Christina Messiou (C)

Radiology department, The Royal Marsden NHS Foundation Trust, London, UK.

Aisha Miah (A)

Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Matthew Orton (M)

MRI unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.

Rick Haas (R)

Sarcoma Unit, Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands.

Khin Thway (K)

Molecular pathology, The Royal Marsden NHS Foundation Trust, London, UK.

Georgina Hopkinson (G)

MRI unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.

Shane Zaidi (S)

Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Myles Smith (M)

Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Elizabeth Barquin (E)

Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Eleanor Moskovic (E)

Radiology department, The Royal Marsden NHS Foundation Trust, London, UK.

Nicos Fotiadis (N)

Department of Interventional Radiology, The Royal Marsden NHS Foundation trust, London, UK.

Dirk Strauss (D)

Sarcoma/Melanoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Andrew Hayes (A)

Sarcoma/Melanoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.

Maria A Schmidt (MA)

MRI unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH